Hot Features
Cellectis S.A., a clinical stage biotechnological company, develops products based on gene-editing with a portfolio of allogeneic chimeric antigen receptor T-cells product candidates in the field of immuno-oncology and gene therapy product candidates in other therapeutic indications. The company is ... Cellectis S.A., a clinical stage biotechnological company, develops products based on gene-editing with a portfolio of allogeneic chimeric antigen receptor T-cells product candidates in the field of immuno-oncology and gene therapy product candidates in other therapeutic indications. The company is developing BALLI-01, to evaluate the safety, expansion, persistence, and clinical activities of lasme-cel in patients with r/r ALL; NatHaLi-01, designed to evaluate the safety, expansion, persistence, and clinical activity of eti-cel in patients with relapsed or refractory B-Cell Non-Hodgkin's Lymphoma (B-NHL). It also develops ALPHA3, targets Large B-Cell Lymphoma (LBCL); TRAVERSE, for the treatment of patients with advanced or metastatic clear cell renal cell carcinoma (RCC). In addition, the company Melanoma, for treatment of unresectable or metastatic melanoma. Cellectis S.A. was founded in 1999 and is headquartered in Paris, France. Show more
| Période | Variation | Variation % | Ouver. | Haut | Bas | Moyenne Vol. Quot. | VWAP | |
|---|---|---|---|---|---|---|---|---|
| 1 | -0.58 | -15.9340659341 | 3.64 | 3.64 | 3.05 | 68747 | 3.25967111 | CS |
| 4 | -0.78 | -20.3125 | 3.84 | 4.19 | 3.05 | 42928 | 3.54393518 | CS |
| 12 | -0.47 | -13.3144475921 | 3.53 | 4.5499 | 2.99 | 36781 | 3.69731299 | CS |
| 26 | -1.71 | -35.8490566038 | 4.77 | 5.45 | 2.99 | 48871 | 4.06694262 | CS |
| 52 | 1.61 | 111.034482759 | 1.45 | 5.4796 | 1.3271 | 99458 | 3.3654964 | CS |
| 156 | 1.02 | 50 | 2.04 | 5.4796 | 0.962777 | 252552 | 2.5760752 | CS |
| 260 | -11.61 | -79.1411042945 | 14.67 | 16.45 | 0.962777 | 217372 | 3.8082735 | CS |
Les dernières valeurs consultées apparaîtront dans cette boîte, vous permettant de choisir facilement les titres vus auparavant.
Assistance: support@advfn.fr
En accédant aux services disponibles de ADVFN, vous acceptez les Conditions Générales de ADVFN Conditions Générales
Vous avez déjà un compte? Connexion
Vous n'avez pas de compte ? Inscription
En m'inscrivant, je confirme avoir lu, compris et accepté les Conditions générales d'ADVFN et j'affirme etre un investisseur privé.